6 research outputs found
Expression of DNMTs in non-cancerous brain tissue specimen and in malignant glioma.
<p>cDNA was synthesized from amplified RNA purified from tumor tissue
obtained by stereotactic biopsy or open surgery and expression of DNMTs
was determined using real-time PCR. <b>A:</b> Expression pattern
of DNMTs in normal brain tissue (1, Nβ=β10) and in
high grade glioma (2, Nβ=β63). DNMT mRNA expression
is calculated relative to the reference genes <i>SDHA</i> and
<i>TBP</i> (*, p>0.01). <b>B:</b> Expression
of DNMTs in non-cancerous brain tissue specimen (1,
Nβ=β10), in high grade glioma (2,
Nβ=β63), and in the glioma group stratified by
<i>MGMT</i> promoter methylation status (methylated, 3,
Nβ=β32; unmethylated, 4,
Nβ=β31). All data were normalized to the reference
genes SDHA and TBP, and the fold change of every DNMT relative to the
median expression in the normal brain samples (arbitrarily set to 1) was
calculated. Horizontal bars indicate medians.</p
Study population.
<p>Abbreviations: KPS, Karnofsky performance score; PE, stereotactic
biopsy; OP, open tumor resection.</p><p>*after 3 months.</p
MGMT mRNA expression and MGMT promoter methylation status in malignant glioma.
<p>Horizontal bars indicate medians. The dotted line indicates the cut-off
value distinguishing low from high MGMT expression values.
<b>A:</b> Expression of MGMT determined with quantitative
real-time PCR in non-cancerous brain tissue specimen (1,
Nβ=β10), in malignant glioma (2,
Nβ=β63), and in the glioma group stratified by
<i>MGMT</i> promoter methylation status (methylated, 3,
Nβ=β32, and unmethylated, 4,
Nβ=β31). cDNA was synthesized from amplified RNA
purified from tumor tissue obtained by stereotactic biopsy or open
surgery and relative expression of MGMT with respect to expression of
the reference genes <i>SDHA</i> and <i>TBP</i> was
determined using real-time PCR. <b>B:</b> Validation set obtained
from the TCGA database. All data were derived from array analyses and
expression levels of methylated (3, Nβ=β105) and
unmethylated (4, Nβ=β104) GBM tissue samples are
shown.</p
Favorable prognostic factors (uni- and multivariate models).
<p>Favorable prognostic factors (uni- and multivariate models).</p
Kaplan-Meier estimates of 63 patients with malignant glioma.
<p>Tumor tissue obtained either by stereotactic biopsy or by open surgery.
<b>A:</b> Progression free survival and overall survival of
the whole study population, <b>B:</b> Overall survival stratified
by the <i>MGMT</i> promoter methylation status.</p
Kaplan-Meier estimates of patients with malignant glioma stratified by MGMT mRNA expression.
<p>Tumor tissue obtained either by stereotactic biopsy or by open surgery
<b>A:</b> Progression free survival
(Nβ=β63), <b>B:</b> Overall survival
(Nβ=β63), <b>C:</b> Progression free survival
of patients with methylated GBMs (Nβ=β24)
<b>D:</b> Survival of patients with methylated GBMs
(Nβ=β24).</p